Vascular Pharmaceuticals is a pioneering brand focused on addressing the complications of diabetes, particularly diabetic nephropathy. As one of the most common complications of diabetes, this type of kidney disease significantly impacts individuals living with Type 1 and Type 2 diabetes, with no current cure available. With a strong commitment to improving the lives of people with diabetes, Vascular Pharmaceuticals aims to help them live longer and healthier lives.

Their lead candidate, VPI-2960B, is currently in Phase 2 clinical trials. Animal studies conducted on diabetic nephropathy models have shown promising results, indicating that VPI-2690B may potentially halt and even reverse the progression of this condition. Vascular Pharmaceuticals recognizes the urgent need for more effective treatment options for diabetics, and their dedication to exploring the benefits of this breakthrough candidate reflects their commitment to providing solutions that make a real difference in patients' lives.

© Vascular Pharmaceuticals. All rights reserved